Trouver un essai clinique

Ipsen mène des essais cliniques pour faire avancer la science et apporter de nouvelles options innovantes aux patients

Vous trouverez sur cette page l’ensemble des études cliniques sponsorisés par Ipsen ou acquis par Ipsen. Vous pouvez utiliser le menu déroulant ci-dessous pour trouver des essais cliniques en sélectionnant un(e) ou plusieurs  indications , statut d’étude, phase de l’étude ou pays participants.

Pour les études cliniques terminées pour lesquels les résultats sont disponibles  , un résumé des résultats est accessible en cliquant sur le bouton «  Lire le résumé » .

Vous pourrez aussi trouver un résumé scientifique des résultats sur les registres cliniques Europe  et US.

Le ‘statut’ de recrutement des participants est défini comme suit :

  • Not yet recruiting – Le recrutement n’a pas commencé
  • Recruiting – Le recrutement est ouvert
  • Enrolling by invitation – Le recrutement est ouvert à une population spécifique qui est invitée à participer
  • Active, not recruiting – Le recrutement est fermé, Les participants sont  toujours suivis dans l’étude
  • Terminated – l’étude a été arrêtée prématurément
  • Completed – l’étude est terminée

Last Data Refreshed @ 12-Apr-2024 06:56:06 UTC

Filtres

Condition

Statut

Phase

Country

Showing : 15 de 152 clinical trials

Follicular Lymphoma

Refractory Follicular Lymphoma

Tazverik

United States of America (the)United States of America (the)


Not Yet Recruiting

Not Yet Recruiting

A study to assess efficacy and safety of oral tazemetostat in adult participants with relapsed/refractory follicular lymphoma that does not have an “EZH2 gain-of-function” genetic mutation

The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an “EZH2” genetic mutation. Follicular lymphoma is a blood cancer. It affects white blood cells called lymphocytes. White blood cells normally help to fight infections, but when you have follicular lymphoma, the blood cells can form tumours in your body. ‘Relapsed/refractory’ follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous treatment. Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the “EZH2” mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an “EZH2” genetic mutation and who previously received therapies commonly used in the U.S. in your body. ‘Relapsed/refractory’ follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous – 5 – SM D form protocol master data -INT / Version 1 treatment. Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the “EZH2” mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an “EZH2” genetic mutation and who previously received therapies commonly used in the U.S. In this study, all participants will receive the study drug. It will be taken by mouth (orally), as a tablet, twice daily. The sizes and number of tumours according to scan results will be collected as well as results of safety tests (such as physical examinations and laboratory tests). The study consists of 3 or 4 periods: ? Screening period may take up to 4 weeks and require at least 1 visit. ? Treatment period will require 2 visits for each of the first 2 months, followed by 1 visit every month for the remainder of the first 6 months, followed by 1 visit every 3 months (except for women of childbearing potential [WOCBP], who will continue to have a visit every month) until unacceptable toxicity, disease progression, or the start of new systemic anticancer therapy, whichever is first. ? Safety follow -up period will last for 1 month after the last dose of tazemetostat, and it will end with 1 visit or telephone call. ? Long -term follow -up period is only for participants who stop taking tazemetostat while their disease continues to respond; this period will last until disease progression, start of new cancer treatment, or death from any cause, whichever is first. Tazemetostat will be provided to participants who tolerate it for as long as their disease does not progress. Participants may be transferred to another study or program after about 2 years for continued treatment with tazemetostat or for long-term follow-up. Patients may withdraw consent to participate at any time.

Primary Sclerosing Cholangitis

ritivixibat

ItalyItaly

FranceFrance

SpainSpain


Recruiting

Recruiting

Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC). Detailed Description: The primary goal of this study in participants with PSC who are treated with A3907 is to assess the safety and tolerability of A3907 following repeat doses. Secondary goals include evaluation of the pharmacokinetic properties of A3907 (the study of how the body interacts with A3907 for the entire duration of exposure) and changes in safety parameters via laboratory testing such as liver enzymes, bile acid levels and markers of bile acid synthesis.

Biliary Atresia

Bylvay

TurkeyTurkey

Netherlands (Kingdom of the)Netherlands (Kingdom of the)

MalaysiaMalaysia

IsraelIsrael

HungaryHungary

Korea (the Republic of)Korea (the Republic of)

AustraliaAustralia

ItalyItaly

CanadaCanada

ChinaChina

Taiwan (Province of China)Taiwan (Province of China)

GermanyGermany

FranceFrance

United States of America (the)United States of America (the)

United Kingdom of Great Britain and Northern Ireland (the)United Kingdom of Great Britain and Northern Ireland (the)

BelgiumBelgium

PolandPoland

New ZealandNew Zealand

SpainSpain


Recruiting

Recruiting

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy. Detailed Description: Up to 70 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

Melanoma | Head And Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Colorectal Cancer | Solid Tumor

IPN01194

SpainSpain

United States of America (the)United States of America (the)

FranceFrance

ChinaChina


Recruiting

Recruiting

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. ‘Advanced solid tumours’ refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally). Detailed Description: The study consists of two parts, called Phase I and Phase IIa. Phase I is designed to assess the safety of increasing doses of IPN01194 in participants with specific types of advanced solid tumours. The aim of this “dose escalation” phase is to find the dose range showing activity on the tumor that can be tolerated by the participants, and to determine the two doses for further testing in Phase IIa. Phase I will assess how the body processes and responds to the study drug when administered with and without food. In Phase IIa, participants with selected single tumour type will be invited to take part. During this phase, the two dose levels of the study drug identified from Phase I will be tested. Participants will take the study drug one of the two dose levels. Each participant will be assigned to a dose level at random (by chance). Each phase will consist of three periods: 1- A period to assess eligibility (screening period) that will take up to 28 days. 2- A treatment period of at least 28 days that will require at least two visits for the first month followed by one visit every month. There will be also one visit, at the end of treatment, at least 30 days after the last administration of study drug. 3- A follow-up period (Phase IIa participants only), where every 3 months, participants will be contacted by phone, until death or the study cut-off date, whichever comes first. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. If in the opinion of the investigator a participant is continuing to experience clinical benefit after the cut-off date, the participant may remain in the study and continue to receive the study drug until either disease progression, unacceptable toxicity or other withdrawal criteria are met.

Upper Limb Spasticity

Dysport

CanadaCanada

FranceFrance

United States of America (the)United States of America (the)


Recruiting

Recruiting

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.